PanaMab, based in Houston, Texas, is a biotech company incorporated in the State of Delaware in May 2013. Our primary focus is on the discovery and development of monoclonal antibodies (mAb) for the treatment of cancer and other severe diseases that have highly unmet medical needs.
Based on an exclusive global licensing agreement with the University of Texas Health Science Center at Houston (the UTHealth) and the University of Texas Southwestern (the UTSW), PanaMab is developing first-in-class mAb product candidates for the treatment of cancer and other diseases.
In addition, PanaMab has a separate exclusive global licensing agreement with the UTHealth to develop potentially best-in-class mAb product candidates for the treatment of cancer.
All of our programs are currently in pre-clinical stage. PanaMab will utilize internal expertise, seek investors, and collaborate with scientists, institutions and biopharmaceutical companies to speed up the drug development process for our product candidates.
PanaMab has filed several patents covering our technology and product candidates.
As of March 1, 2016, PanaMab has been selected as a member of the J Lab that is sponsored by Johnson & Johnson for the start-up companies in Houston area.